Macular Neovascularization Secondary to Subclinical Angioid Streaks in Age-Related Macular Degeneration: Treatment Response to Anti-VEGF at 2-Year Follow-up.
Age-related macular degeneration
Angioid streaks
Biomarker
Macular neovascularization
Multimodal imaging
OCT
Reticular pseudodrusen
Subclinical angioid streaks
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
25
01
2024
accepted:
20
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
7
3
2024
Statut:
aheadofprint
Résumé
To characterize the response to antivascular endothelial growth factor (VEGF) treatment of macular neovascularization (MNV) secondary to age-related macular degeneration (AMD) with subclinical angioid streaks (AS) during a 2-year follow-up. Retrospective, longitudinal, case-control, and multicentric study. Among a cohort of neovascular AMD population, we selected patients with subclinical AS and treatment-naïve MNV treated with anti-VEGF for a 2-year follow-up. An age- and sex-matched control group with treatment-naïve MNV secondary to AMD without subclinical AS was selected. Demographics and differences in treatment response (i.e., number of injections needed, anatomical and functional outcomes) between the two groups were analyzed. Among 102 eyes of 102 patients with neovascular AMD, 34 eyes of 34 patients (82 ± 6 years old) were included in the subclinical AS group, whereas 68 eyes of 68 patients (81 ± 6 years old, p = 0.342) in the control group. All eyes with subclinical AS presented RPD compared to 56% of eyes without subclinical AS (p < 0.001). During the 2-year follow-up, eyes with subclinical AS needed more injections (10.6 ± 3.2 vs 8.3 ± 3.1 injections for eyes with and without subclinical AS, respectively, p < 0.001). Visual acuity (VA) decreased during the treatment (from 0.53 ± 0.37 at the baseline to 0.69 ± 0.45 LogMAR at 2-year follow-up, p = 0.044) in eyes with subclinical AS; no VA changes were observed in the control group (p = 0.798). RPE atrophy at the end of the 2-year follow-up affected 74% of cases with subclinical AS and 29% of cases of the control group (p < 0.001). MNVs secondary to AMD with subclinical AS are characterized by worse functional and anatomical outcomes after 2-year anti-VEGF treatment compared to MNV secondary to AMD without subclinical AS, supporting the different pathophysiological mechanisms involved in this recently described AMD phenotype.
Identifiants
pubmed: 38451452
doi: 10.1007/s40123-024-00918-x
pii: 10.1007/s40123-024-00918-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51.
doi: 10.1016/j.ophtha.2012.10.036
pubmed: 23332590
Friedman E. The pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2008;146:348–9.
doi: 10.1016/j.ajo.2008.05.017
pubmed: 18724980
Sacconi R, Corbelli E, Borrelli E, et al. Choriocapillaris flow impairment could predict the enlargement of geographic atrophy lesion. Br J Ophthalmol. 2021;105:97–102.
doi: 10.1136/bjophthalmol-2019-315800
pubmed: 32201374
Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging. 2014;35:2562–73.
doi: 10.1016/j.neurobiolaging.2014.05.003
pubmed: 24925811
McLeod DS, Grebe R, Bhutto I, et al. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982–91.
doi: 10.1167/iovs.09-3639
pubmed: 19357355
Sacconi R, Vella G, Battista M, et al. Choroidal vascularity index in different cohorts of dry age-related macular degeneration. Transl Vis Sci Technol. 2021;10(12):26.
doi: 10.1167/tvst.10.12.26
pubmed: 34665234
pmcid: 8543393
Sacconi R, Tombolini B, Zucchiatti I, et al. Subclinical angioid streaks with pseudodrusen: a new phenotype of age-related macular degeneration. Ophthalmol Ther. 2023;12(5):2729–43.
doi: 10.1007/s40123-023-00778-x
pubmed: 37542615
pmcid: 10441970
Servillo A, Zucchiatti I, Sacconi R, et al. The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration. Expert Opin Pharmacother. 2023;24(2):197–206.
doi: 10.1080/14656566.2022.2154145
pubmed: 36469544
Corbelli E, Carnevali A, Marchese A, et al. Optical coherence tomography angiography features of angioid streaks. Retina. 2018;38:2128–36.
doi: 10.1097/IAE.0000000000001859
pubmed: 28961674
Rohart C, Le HM, Estrada-Walker J, Giocanti-Auregan A, Cohen SY. Long-term prognosis of choroidal neovascularization complicating angioid streaks. Retina. 2023;43(6):882–7.
doi: 10.1097/IAE.0000000000003746
pubmed: 36727798
Sekfali R, Mimoun G, Cohen SY, et al. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks. Eur J Ophthalmol. 2020;30(3):550–6.
doi: 10.1177/1120672119838133
pubmed: 30880436
Ramakrishnan T, Chandra S, Sivaprasad S. Long-term follow-up of management of choroidal neovascularisation secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor. Eye (Lond). 2021;35(3):853–7.
doi: 10.1038/s41433-020-0979-9
pubmed: 32461565
Barresi C, Borrelli E, Fantaguzzi F, et al. Complications associated with worse visual outcomes in patients with exudative neovascular age-related macular degeneration. Ophthalmologica. 2021;244(6):512–22.
doi: 10.1159/000519518
pubmed: 34517374
Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A. Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol. 2009;93(2):155–8.
doi: 10.1136/bjo.2008.145896
pubmed: 18971232
Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol. 2009;148(4):584-590.e2.
doi: 10.1016/j.ajo.2009.04.026
pubmed: 19541288
Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol. 2009;93(1):47–51.
doi: 10.1136/bjo.2008.143461
pubmed: 18971238
Tilleul J, Mimoun G, Querques G, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: four-year follow-up. Retina. 2016;36(3):483–91.
doi: 10.1097/IAE.0000000000000745
pubmed: 26355947
Parodi MB, Cicinelli MV, Marchese A, et al. Intravitreal aflibercept for management of choroidal neovascularization secondary to angioid streaks: the Italian EYLEA-STRIE study. Eur J Ophthalmol. 2021;31(3):1146–53.
doi: 10.1177/1120672120928305
pubmed: 32483995
Sacconi R, Brambati M, Miere A, et al. Characterisation of macular neovascularisation in geographic atrophy. Br J Ophthalmol. 2022;106(9):1282–7.
doi: 10.1136/bjophthalmol-2021-318820
pubmed: 33836986
Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125(6):878–86.
doi: 10.1016/j.ophtha.2017.12.026
pubmed: 29477692
Querques L, Parravano M, Borrelli E, et al. Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes. Br J Ophthalmol. 2020;104(1):47–52.
doi: 10.1136/bjophthalmol-2018-313685
pubmed: 31000509
Evans RN, Reeves BC, Maguire MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138(10):1043–51.
doi: 10.1001/jamaophthalmol.2020.3001
pubmed: 32816002
pmcid: 7441468
Schmidt-Erfurth U, Reiter GS, Riedl S, et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 2022;86: 100972.
doi: 10.1016/j.preteyeres.2021.100972
pubmed: 34166808
Sacconi R, Fragiotta S, Sarraf D, Sadda SR, Freund KB, Parravano M, Corradetti G, Cabral D, Capuano V, Miere A, Costanzo E, Bandello F, Souied E, Querques G. Towards a better understanding of non-exudative choroidal and macular neovascularization. Prog Retin Eye Res. 2023;92: 101113.
doi: 10.1016/j.preteyeres.2022.101113
pubmed: 35970724
Sacconi R, Corbelli E, Carnevali A, Querques L, Bandello F, Querques G. Optical coherence tomography angiography in geographic atrophy. Retina. 2018;38:2350–5.
doi: 10.1097/IAE.0000000000001873
pubmed: 29016457
Vujosevic S, Alovisi C, Chakravarthy U. Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration. Acta Ophthalmol. 2023;101(8):839–56.
doi: 10.1111/aos.15767
pubmed: 37933608
Lad EM, Finger RP, Guymer R. Biomarkers for the progression of intermediate age-related macular degeneration. Ophthalmol Ther. 2023;12(6):2917–41.
doi: 10.1007/s40123-023-00807-9
pubmed: 37773477
pmcid: 10640447
Sacconi R, Battista M, Borrelli E, et al. Choroidal vascularity index is associated with geographic atrophy progression. Retina. 2022;42(2):381–7.
doi: 10.1097/IAE.0000000000003305
pubmed: 34561405